Regulatory alerts

Durvalumab recommended for non-small-cell lung cancer

NICE has recommended durvalumab for the maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation in final draft guidance, which reviewed the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for the treatment.
Go to the profile of OnMedica
May 13, 2022